Acute myeloid leukemia (AML) with NUP98 fusions (NUP98-r) is an aggressive form of blood cancer. It is caused by a chromosomal rearrangement that abnormally fuses the NUP98 gene with other genes, resulting in the formation of NUP98 fusion oncoproteins. Until now, there have been no therapeutic strategies to directly inactivate NUP98 fusion oncoproteins. Researchers from the CeMM Research Center for Molecular Medicine, the University of Veterinary Medicine Vienna and the St. Anna Children's Cancer Research Institute have achieved a breakthrough: they identified the protein SPOP as a direct regulator of the stability of NUP98 fusion oncoproteins, providing a potential target for new therapies. The study was published in the prestigious scientific journal Cell Reports (DOI: 10.1016/j.celrep.2025.116602).

A bold plan to supercharge immune cell ‘spies’ to better seek out and kill cancer cells has received a $17 million funding boost from the Australian Government.

In preclinical studies, researchers found that priming the immune system with a Treg-expanding therapy before stem cell transplant boosted survival, protected vital organs, and promoted a balanced gut microbiome—offering hope for safer, more effective treatment of blood cancers. The study is highlighted on the cover of the Nov. 27, 2025, issue of the journal, Blood.

Electrotherapy using injectable nanoparticles delivered directly into the tumour could pave the way for new treatment options for glioblastoma, according to a new study from Lund University in Sweden. 

Oncolytic viruses (OVs) represent a cutting-edge approach in cancer immunotherapy, characterized by their ability to selectively infect and destroy tumor cells by inducing immunogenic cell death and triggering an anti-tumor immune response, without affecting healthy cells. Of the different OVs, HSV-1 shows promising clinical applications due to its potent oncolytic ability, broad infectivity range, ease of genetic manipulation, induction of long-term cellular immune response, and the availability of drugs to control its proliferation.

A new collaborative study from Pusan National University and Yonsei University suggests that the FOLFIRINOX regimen showed numerically improved survival outcomes compared to current standards such as FOLFOX, FOLFIRI, and nal-IRI/FL, while maintaining manageable toxicity levels. These findings suggest that FOLFIRINOX could serve as a promising second-line treatment option for patients with advanced BTC following first-line chemotherapy failure, warranting further validation through prospective clinical studies.